Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...

Eli Lilly & Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6% plunge — the worst session for the stock in nearly four years.

Eli Lilly, the world’s biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast. Sales of weight-loss drug Zepbound and diabetes drug ...

In Eli Lilly's most recent quarter, which ended on Sept. 30, 2024, it grew its sales by 20% to $11.4 billion. It also had multiple products that generated over $1 billion in revenue, including its ...

Eli Lilly (LLY ... doses of tirzepatide was available throughout Q4," said Lilly CEO David Ricks in a statement. The move in the stock surprised some experts and analysts since the market had ...

Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in $1.9 billion ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first ...